A novel RNA-binding nuclear protein that interacts with the fragile X mental retardation (FMR1) protein

Barbara Bardoni*, Annette Schenck and Jean Louis Mandel

Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, BP 163, 67404 Illkirch Cedex, CU de Strasbourg, France

Received August 20, 1999; Revised and Accepted October 4, 1999


Silenced expression of the FMR1 gene is responsible for the fragile X syndrome. The FMR1 gene codes for an RNA binding protein (FMRP), which can shuttle between the nucleus and the cytoplasm and is found associated to polysomes in the cytoplasm. By two-hybrid assay in yeast, we identified a novel protein interacting with FMRP: nuclear FMRP interacting protein (NUFIP). NUFIP mRNA expression is strikingly similar to that of the FMR1 gene in neurons of cortex, hippocampus and cerebellum. At the subcellular level, NUFIP colocalizes with nuclear isoforms of FMRP in a dot-like pattern. NUFIP presents a C2H2 zinc finger motif and a nuclear localization signal, but has no homology to known RNA binding proteins and shows RNA binding activity in vitro. NUFIP does not interact with the FMRP homologues encoded by the FXR1 and FXR2 genes. Thus, these results indicate a specific nuclear role for FMRP.

INTRODUCTION

The fragile X mental retardation syndrome is a frequent cause of inherited mental retardation affecting ~1 in 4000 males and ~1 in 7000 females in Caucasian populations. In most affected males the syndrome is characterized by moderate to severe mental retardation, characteristic facial features and postpubertal macroorchidism. Behaviour in affected boys is often characterized by hyperactivity and some autistic features. Affected females have in general a milder mental handicap (1). The syndrome is associated with an unstable expansion of a CGG repeat located in the 5′-untranslated region (5′-UTR) of the fragile X mental retardation (FMR1) gene (2–4). The full mutation found in patients is characterized by an abnormal methylation pattern that shuts off transcription of the FMR1 gene (5). FMR1 codes for a series of protein isoforms derived from alternative splicing affecting the presence of exons 12 and 14 and the choice of acceptor sites in exons 15 and 17 (6,7). The largest of these proteins is 632 amino acids long. FMRP is widely, but not ubiquitously, expressed with abundant neuronal expression in brain, in particular in the hippocampus and the cerebellum (8–10). The full-length FMRP protein is localized in the cytoplasm (8), yet nuclear localization has occasionally been observed, and, in transfection studies, FMRP isoforms devoid of exon 14 sequences are localized in the nucleus (8,11).

FMRP contains regions similar to domains previously found in RNA-binding proteins (two KH domains and one RGG box); indeed, it is able to bind RNA homopolymers and some mRNAs (12–14). Recently FMRP was found associated to ribonucleoparticles (RNPs) in actively translating polyribosomes (15,16).

FMRP is endowed with a nuclear localization signal (NLS) (17,18) and a nuclear export signal (NES) (17–19), suggesting that it shuttles between nucleus and cytoplasm (20) and may be implicated in mRNA export from nucleus to cytoplasm. Alternatively a possible role in modulating the localization, stability and/or translation of its target mRNAs has also been hypothesized (for a review see ref. 21).

FMR1 is a member of a family of genes, whose other two known members (FXR1 and FXR2) present high levels of similarity to FMR1. Like FMRP, FXR1P and FXR2P contain two KH domains and one RGG box; in addition, it has been demonstrated that FXR1P is associated with polysomes and binds RNA homopolymers in vitro. Comparison of the three proteins in man, mouse and Xenopus shows high level of similarity even in domains of unknown function. The three proteins are able to form homodimers and heterodimers (22–24). The three genes show an overlapping but clearly distinct pattern of expression in brain and testis (25). This suggests that these FMRP-related proteins, although structurally very similar, may have distinct functions during embryonic or adult life.

Apart from the KH domains, the NES and the RGG box, no specific function or features have been ascribed to other regions of FMRP that are well conserved in evolution. Such high level of conservation suggests that they may take part in protein–protein interactions. The NLS has been mapped already in the FMRP N-terminal region, but it has not been identified precisely and does not resemble classical NLSs.

A better knowledge of FMRP function is of major importance to understand the mechanism of fragile X syndrome. In order to find novel proteins interacting with FMRP that could play a role in the definition of FMRP function, we used the first 218 amino acids (N-terminal domain) of human FMRP as bait in a two-hybrid system in yeast (26). We have shown previously that a deletion construct corresponding to the first 114 amino acids of FMRP accumulates in the nucleus, suggesting that FMRP has a strong

*To whom correspondence should be addressed. Fax: +33 3 88 65 32 46; Tel: +33 3 88 65 34 14; Email: bardoni@igbmc.u-strasbg.fr
affinity for a nuclear component (18). The 218 amino acid N-terminal region has strong homology with FXR1 and FXR2 (23), is conserved during evolution (23) and contains the NLS activity (18). Here we report the identification of a novel protein interacting with FMRP. We have characterized the interaction between the two proteins both in vitro and in vivo by GST pull-down and co-immunoprecipitation. This FMRP-interacting protein, nuclear FMRP interacting protein (NUFIP), shows no homology to proteins of known function, and contains a C2H2 zinc finger motif and a putative NLS. NUFIP is localized in the nucleus in a dot-like pattern and appears colocalized with the nuclear isoforms of FMRP. NUFIP mRNA is widely expressed in adult tissues; however, results of in situ hybridization experiments in mouse brain show that NUFIP is expressed at high levels in neurons of cortex, hippocampus and Purkinje cells, like the FMR1 gene. NUFIP shows RNA binding activity in vitro.

RESULTS

We have performed a yeast two-hybrid screening to identify putative interactors of the highly conserved N-terminal region of FMRP, which is devoid of identifiable functional motifs, although it contains the NLS activity (17,18).

A yeast expression vector encoding the N-terminal domain of the human FMRP fused to the DNA binding domain of the Escherichia coli transcription factor LexA (pBT-N-ter) was used as a bait. A mouse embryonic [embryonic day (E) 9.5–E12.5] library fused to the VP16 activation domain was used as prey (27). We performed the selection in the yeast strain L40 carrying both HIS3 and LacZ reporters under the control of LexA responsive elements, in the presence of 25 mM 3-aminotriazole. From \( \sim 4 \times 10^6 \) clones screened, \( \sim 300 \) positive colonies corresponding to 10 different clones showed both histidine prototrophy and \( \beta \)-galactosidase activity, including the known interactors FXR1P (50 colonies) and FXR2P (1 colony). In order to test the capacity of our positive clones to interact also with the full-length protein we fused to VP16 a nuclear isoform of FMRP (ISO12) (11). \( \beta \)-galactosidase activity is moderately reduced when the bait is ISO12 (this is also true for the positive control FXR2) (Fig. 1A). However, we observed that ISO12 is less expressed than the N-terminus bait by western blot analysis on yeast protein extracts (data not shown). In addition, no \( \beta \)-galactosidase activity was observed in the yeast strain transformed only with the bait pBT-N-ter and the empty vector pASV3 (Fig. 1A).

Among the novel interacting clones we focused on the one that showed the highest \( \beta \)-galactosidase activity (Fig. 1A), in the same range as that elicited by the FXR2P control. It encodes a full-length protein of 484 amino acids in mouse, and is highly similar to human ESTs defining the orthologous human protein of 495 amino acids (72.8% identity and 81.1% similarity) (Fig. 1B). Two highly conserved domains are present in the middle of the protein (95% identity between man and mouse over 140 amino acids), and toward the C-terminus (100% identity over 42 amino acids). We propose to name these proteins h (human) and m (mouse) NUFIP. The amino acid sequences of the NUFIP proteins show no homology to proteins of known function. Using the PROSITE program, several motifs were found from N- to C-terminus. A conserved proline stretch is present at position 39–44 (mNUFIP) and 44–49 (hNUFIP). This stretch is found in the context of a very proline-rich N-terminal domain. Twenty-seven proline residues are present in the first 105 amino acids of hNUFIP and in the corresponding first 98 amino acids of mNUFIP, 20 of them being at positions conserved between man and mouse. A C2H2 zinc-finger domain is present at position 165–192 (mNUFIP) and 174–201 (hNUFIP). A bipartite NLS is predicted at position 234–251 (mNUFIP) and 243–260 (hNUFIP). All these motifs are very highly conserved between man and mouse (Fig. 1B).

Characterization of the interaction between FMRP and NUFIP

The FMRP full-length protein (ISO1) was expressed as a fusion protein with glutathione S-transferase (GST) in a baculovirus system. The mNUFIP protein was produced and labelled with \(^{[35}S\)methionine by in vitro transcription-translation using rabbit reticulocyte lysate. The GST–FMRP fusion protein immobilized on glutathione–Sepharose was incubated with either labelled mNUFIP or, as a positive control, the in vitro labelled FXR1P or FMRP. As a negative control we used luciferase. mNUFIP bound specifically to the immobilized GST–FMRP, as efficiently as the FMRP positive control (Fig. 2A). No binding to GST was observed. No signal was obtained for luciferase. Using increasing stringency conditions, we showed that mNUFIP, like FXR1P, interacts strongly with FMRP in the presence of 0.2 M NaCl, and interaction is still detectable at 0.5 M NaCl (Fig. 2B). The same results were obtained using hNUFIP (data not shown). In a reverse experiment, an NUFIP–GST column retained efficiently an in vitro translated FMRP isoform (ISO7) (Fig. 2C). Finally, we investigated whether the interaction could be indirect, mediated by RNA (as NUFIP itself has RNA-binding properties; see below). An experiment similar to the one reported in Figure 2A was performed after treatment of in vitro translated NUFIP and GST–FMRP beads with RNase A (100 µg/ml), RNase T1 (40 U/ml) and DNase (100 µg/ml). This resulted only in a slight reduction of binding at 150 mM NaCl (also observed for an FXR1P positive control) (data not shown), indicating that a direct protein–protein interaction is indeed present.

We confirmed the interaction by co-immunoprecipitation in COS cells cotransfected with a vector expressing the hNUFIP full-length cDNA or its deletion constructs (Fig. 3A) and with a vector expressing ISO12, a nuclear isoform of FMRP (11). For this experiment we raised an anti-NUFIP antibody against a synthetic polypeptide corresponding to the C-terminus of the human NUFIP protein (amino acids 421–442). One rabbit antiserum was obtained and, after purification on an affinity column, its specificity was determined by both immunoblotting and immunofluorescence staining using HeLa and COS cells transfected with an expression vector for hNUFIP.

Cell extracts from cotransfected COS cells were immunoprecipitated using the polyclonal anti-NUFIP antibody (no. 1375), followed by immunoblotting with the monoclonal anti-FMRP antibody 1C3 (8). The control was performed by co-immunoprecipitation of the same cell extracts using a polyclonal anti-huntingtin antibody (no. 566) (28). ISO12 was co-immunoprecipitated by the anti-NUFIP antibody, but not
Figure 1. (A) β-galactosidase activity test for interaction in the two-hybrid system. Baits were the N-terminal region of FMRP and ISO12 (nuclear isoform of FMRP) and preys were mouse FXR2P (bars 1 and 3) (derived from clone N21 in our two-hybrid screening) and NUFIP (bars 2 and 4) (corresponding to clone N43 in our two-hybrid screening). The negative controls (bars 5–7) were, respectively, the two baits alone and the prey with lamin fused to the DNA binding domain of LexA. (B) Alignment of human and mouse NUFIP amino acid sequences. The putative C2H2 zinc finger and NLS are indicated. The cDNAs were established as described in Materials and Methods.
by the unrelated antibody, in cell extracts obtained from COS cotransfected with full-length or different C-terminal deletion constructs of NUFIP (Fig. 3B and C). These experiments substantiated the in vivo interaction between NUFIP and FMRP and indicate the presence of an interaction region in the C-terminal half of NUFIP (Fig. 3C). In the same set of experiments, an N-terminal huntingtin construct could not be co-immunoprecipitated with ISO12 (data not shown). In other GST pull-down experiments, we found that both a C-terminal construct (254–495 amino acids) and an N-terminal construct (1–254 amino acids) are able to interact efficiently at 250 mM NaCl with GST–FMRP (data not shown), suggesting that two FMRP-interacting domains in NUFIP could exist.

To further test the ability of NUFIP to interact in vivo with FMRP, we co-immunoprecipitated the endogenous proteins. HeLa cell extract was immunoprecipitated with the polyclonal antibody no. 1375 (anti-NUFIP) and with the antibody no. 566.
strain with to the FMR1P N-terminus. We cotransformed the L40 yeast signal in poly(A) + RNAs from 16 different human tissues (Fig. 2A).

Expression of the NUFIP and FXR1P or FXR2P in presence of 100 mM NaCl (Fig. 2C). We did not observe interaction between hNUFIP in vitro (produced in bacteria) and GST pull-down experiments using hNUFIP fused to GST was observed. To confirm these results, we performed some level comparable with the bait (pBT-N-ter) expression level of FXR2P and FXR1P by immunoblotting of yeast to homo- and heterodimerize. We also tested the expression in two-hybrid screening. As expected, each construct was able FXR1P and FXR2P (N27 and N21, respectively) that we found used as a positive control the mouse clones corresponding to FXR1 or FXR2 deletion constructs and the mNUFIP (clone N43). Interaction between mNUFIP and FXR1P or FXR2P was tested by evaluation of the β-galactosidase activity in cotransformed yeast colonies. No β-galactosidase activity was observed in all analysed colonies. In this experiment, we used as a positive control the mouse clones corresponding to FXR1P and FXR2P (N27 and N21, respectively) that we found in two-hybrid screening. As expected, each construct was able to homo- and heterodimerize. We also tested the expression level of FXR2P and FXR1P by immunoblotting of yeast protein extract (using an anti-lexA antibody): an expression level comparable with the bait (pBT-N-ter) expression level was observed. To confirm these results, we performed some GST pull-down experiments using hNUFIP fused to GST (produced in bacteria) and in vitro translated human FXR1P and FXR2P. We did not observe interaction between hNUFIP and FXR1P or FXR2P in presence of 100 mM NaCl (Fig. 2C).

Expression of the NUFIP gene

Northern blot hybridization using mNUFIP cDNA as a probe detected in total RNA from mouse cerebellum a transcript of ~1.8 kb (data not shown), a length similar to the 1657 bp cDNA sequence derived from the analysis of 7 cDNA clones (see Materials and Methods).

A human cDNA sequence of 3462 bp [ending with a poly(A) tail] was derived from two overlapping ESTs. Northern blot hybridization using hNUFIP cDNA as a probe detected a signal in poly(A)+ RNAs from 16 different human tissues (Fig. 4). Bands of ~1.8, ~3.5 and ~5 kb were observed in various tissues suggesting the presence of alternatively spliced or polyadenylated mRNA species. Indeed four human EST sequences occur 18 bp after an AATAAA polyadenylation signal present at position 1655 (the first nucleotide of the initiation codon is taken as position 1) and thus corresponding to the ~1.8 kb band. For brain RNA a single band was observed at ~3.5 kb corresponding to the length of the sequenced cDNA (from a neuronal cell line library) (Fig. 4).

We also compared the distribution of the FMR1 and the mNUFIP transcript by in situ hybridization on mouse brain sections using RNA probes labelled with digoxigenin. For both probes, strong labelling of neurons was observed in hippocampus and in cortex (Fig. 5A). In the cerebellum, the two genes were highly expressed in Purkinje cells, whereas, in the granular cell layer, FMR1 expression appears comparatively higher than that of NUFIP (Fig. 5B and C). Expression of both genes in the molecular layer appeared very low. These findings indicate that NUFIP is expressed in neurons and not in glial cells in the brain, similarly to FMR1.

Subcellular localization of NUFIP

An expression vector encoding the mNUFIP clone fused to green fluorescent protein (GFP) was used in transfection experiments in HeLa cells. The fusion protein was localized in the nucleus in a dot-like distribution (Fig. 6E), and colocalized with cotransfected FMRP nuclear isoform ISO12 (Fig. 6A–C). The same results were obtained transfecting cells with hNUFIP cloned in a eucaryotic expression vector and revealed using the polyclonal no. 1375 antibody (Fig. 6I) and in cotransfected (anti-huntingtin) (28), followed by immunoblotting with the same antibodies and the polyclonal 1C3 (anti-FMRP) (8) (Fig. 3D).

Figure 4. Northern blot analysis of NUFIP expression in human tissues; hNUFIP cDNA was used as a probe on a blot containing poly(A)+ RNA from different tissues (Clontech). Lane 1, spleen; lane 2, thymus; lane 3, prostate; lane 4, testis; lane 5, ovary; lane 6, small intestine; lane 7, colon (mucosal lining); lane 8, peripheral blood leukocyte; lane 9, heart; lane 10, brain; lane 11, placenta; lane 12, lung; lane 13, liver; lane 14, skeletal muscle; lane 15, kidney; lane 16, pancreas. After hybridization in ExpressHyb Hybridization Solution (Clontech), the blots were washed twice in 0.2% SSC, 0.1% SDS at 65°C.

Figure 5. In situ hybridization using digoxigenin-labelled FMR1 and NUFIP probes. (A) Expression in hippocampus. Part of the cortex labelling is visible in the right corner. (B) Expression in cerebellum. (C) Magnification of cerebellum: P, Purkinje cell; mcl, molecular cell layer; gcl, granular cell layer.
cells with ISO12 (Fig. 6F–H). In cells transfected only with FMRP ISO12 a more homogeneous nuclear staining of ISO12 was observed by conventional immunofluorescence on confocal microscopy (Fig. 6D) or on light microscopy (Fig. 6I). These results suggest that nuclear localization of FMRP may be modulated by interaction with NUFIP.

RNA-binding activity of NUFIP

The zinc-finger motif is known to be an RNA-binding module in some cases. To investigate the capacity of NUFIP to bind to RNA homopolymers in vitro, we synthesized mNUFIP in a wheat germ system (lacking endogenous FMRP). Full-length mNUFIP protein binds poly(G) and, less efficiently, poly(U), but not poly(A) or poly(C) (Fig. 7A). This result was confirmed in an RNA homopolymer-binding assay using histag-hNUFIP expressed in bacteria, revealed by the anti-NUFIP antibody. The binding to poly(G) was more efficient than binding to poly(U) (data not shown). This pattern of binding appears similar to that observed previously for FMRP (12,13,29).

hNUFIP fused to GST and produced in bacteria was also used to carry out a north-western experiment. The recombinant protein interacts with RNA in this assay as well as FMRP, while no binding was observed for GST (Fig. 7B) and an unrelated protein, ovalbumin (data not shown).

DISCUSSION

FMRP is an RNA-binding protein having both an NLS and an NES, which led to the suggestion that it shuttles between the nucleus and cytoplasm (17–19). However, all the isoforms detectable at the protein level in vivo appear cytoplasmic (8,11). In the cytoplasm, FMRP is associated to actively translating polysomes via RNA, being part of an RNP complex (15,16). FMRP is thought to be implicated in mRNA export from nucleus to cytoplasm (for a review see ref. 21). However, the precise physiological role of FMRP is unknown, and it is also unknown whether FMRP is involved in RNA metabolism in the nucleus. The ‘nuclear’ isoforms lacking the NES whose existence was predicted by RT–PCR, have not been unequivocally detected in vivo (11) and are likely to be present only at low level.

Only two proteins interacting with FMRP have been identified previously: FXR1P and FXR2P, showing high similarity to FMRP and probably endowed with a related but distinct function (22,23,25,30).

Our previous results suggested that the FMRP N-terminal region, which contains the NLS activity and the homo- or heterodimerization domain but lacks known functional motifs, has an affinity for the nucleus (18). Using the yeast two-hybrid assay to identify novel proteins that interact with the N-terminal domain of FMRP, we identified 10 positive clones, including the known interactors FXR1P and FXR2P. The best interactor was a novel nuclear protein, NUFIP, which presents no homology with known proteins. It contains a bipartite NLS and a C2H2 zinc-finger motif. NUFIP is localized in the nucleus in a dot-like pattern and colocalizes with FMRP nuclear isoforms in transfection assays. In transfection experiments, nuclear FMRP isoforms, such as ISO12 (11), show a homogeneous distribution in the nucleus, excluding the

Figure 6. Confocal (A–E) and light (F–J) microscopy analysis of HeLa cells transiently transfected with ISO12 (FMRP nuclear isoform), mNUFIP fused to GFP (GFP–mNUFIP) and hNUFIP cloned in pTL1. ISO12 was revealed by monoclonal antibody 1C3 (B, D, G and I), whereas hNUFIP was revealed by polyclonal antibody no. 1375 (F–J). (A) Nuclear pattern of GFP–mNUFIP in cell cotransfected with ISO12. (B) Nuclear pattern of FMRP ISO12 in cell cotransfected with GFP–mNUFIP. The combined images are shown in (C). HeLa cells transfected with the ISO12 alone (D) and with GFP–mNUFIP alone (E). (F) Nuclear pattern of hNUFIP in cell cotransfected with ISO12. (G) Nuclear pattern of FMRP ISO12 in cell cotransfected with hNUFIP. The combined images are shown in (H). HeLa cells transfected with the ISO12 alone (I) and with hNUFIP alone (J).
nucleolus. When cotransfected with NUFIP, FMRP ISO12 shows a dot-like distribution, perfectly overlapping with that of its nuclear partner, indicating that co-expression in the nucleus may target the latter to specific subdomains relevant for its putative nuclear function.

The interaction between the two proteins was confirmed in vitro by GST pull-down experiments and in vivo by co-immunoprecipitation in mammalian cells and it is still present under high salt conditions. Our failure to detect interaction between FXR1P or FXR2P and NUFIP is surprising, given the high degree of similarity of FXR1P and FXR2P to FMRP. It will thus be interesting to map more precisely the site of interaction in the N-terminal domain of FMRP. Recent results from Tamanini et al. (20) suggest that FXR2P localizes to the nucleolus when nuclear export is inhibited. It is therefore possible that the three homologous proteins interact with different proteins/sites within the nucleus and may thus have specialised rather than overlapping functions.

In mouse adult brain, FMR1 and NUFIP genes show a very similar neuronal expression pattern, with high expression in regions involved in cognitive function (cortex and hippocampus). This suggests that the interaction between FMRP and NUFIP is relevant for neuronal function in vivo.

We have also shown that NUFIP can bind RNA in vitro, and it could thus be involved in RNA metabolism in the nucleus. Mutation of the mNUFIP zinc finger does not prevent the binding of the in vitro translated product to poly(G) and poly(U) (our unpublished data), suggesting that a novel RNA binding motif may be present in this protein.

A current accepted model suggests that FMRP binds some specific mRNAs in the nucleus and then moves to the cytoplasm as part of an RNP complex, where it is involved in delivery of mRNA to ribosomes (21). It will be important to determine whether NUFIP is part of such a nuclear RNP complex together with FMRP and/or whether the NUFIP/FMRP complex may play a specific role in post-transcriptional modification of the nucleus. Recently PML bodies were found to be the nuclear regions in which nascent RNA is present (31). Thus, it could be interesting to study whether nascent RNA is present in the nuclear dots in which NUFIP is localized. The identification of the nuclear domain where NUFIP is localized and the definition of the specific RNA sequences bound by FMRP/NUFIP complex will be an important step in the understanding the function of both proteins.

The specificity of interaction with FMRP, exemplified by the apparent absence of interaction with FXR1P and FXR2P, suggests that the lack of this interaction may play a role in the fragile X syndrome phenotype. Furthermore, the NUFIP gene may be a candidate for cases of mental retardation. It will be interesting to study the expression of the NUFIP gene during development in order to correlate its expression to FMR1 expression and to the physical features in the fragile X syndrome. Understanding the function of NUFIP is an essential step in the definition of the molecular and developmental mechanisms by which the absence of FMR1 expression produces the fragile X syndrome.

**MATERIALS AND METHODS**

**Two-hybrid screening in yeast**

An ISO7 construct (11) was digested with EcoRI and XhoI, generating a fragment of 654 bp that was cloned in the vector pBTM116m (27). This construct was named pBT-N-ter.

The yeast strain L40 [his 3D200 topo I-901 leu2-3, 112 ade2 lys::(lexAop)4·HIS3 ura3::(lexAop)8·lacZ gal4·gal80] was transformed into the yeast strain L40 already harbouring pBT-N-ter. The transformants were plated onto appropriate selective medium (SC) supplemented with 25 mM 3-amino-triazole (Sigma, St Quentin Fallavier, France). The cDNAs of positive plasmids were isolated by growing the His+/β-galactosidase colonies in SC media overnight, lysing the cells with acid-washed beads, electrophorating the bacterial strain HB101 (LeuB auxotrophic) with the yeast lysate and plating onto M9 (–Leu) plates (27). Liquid β-galactosidase assays were performed with 10 independent measurements as described (34).

**Expression of recombinant FMRP**

The plasmid ISO1 (11) was amplified using the primers GGGGCTAGCAGGAGGAGCTGATGATGGAAG and GG-GGCTAGCCTAGGTACTCCATTCACGAG, both containing an NheI site. The obtained fragment was digested with NheI and cloned in the PVL1393-GST-HMK-His5 vector (35). The PCR reaction consisted of 1 cycle at 94°C (10 s), 57°C (20 s) and 1 cycle at 72°C (5 min), and was performed using Deep VentR DNA Polymerase (New England Biolabs, Beverly, MA).

SF9 cell infection and whole cell extract preparation was performed as described by O’Reilly (36).

**cDNA sequences of human and mouse NUFIP genes**

Mouse sequence was derived from a 1657 bp cDNA sequence ended by a poly(A) tail established from two hybrid selected

**Figure 7.** RNA-binding activity of m- and hNUFIP. (A) Binding to the RNA homopolymer beads. mNUFIP binds preferentially to poly(G) and, less intensely, to poly(U) in the presence of 0.25 M NaCl. (B) North-western analysis performed using recombinant GST–hNUFIP protein (lane 2), GST alone (lane 3), GST–FMRP (lane 4) and, as probe, RNA transcribed from the poly linker of pBluescript. Lane 1, recombinant GST–hNUFIP was analysed by immunoblotting with antibody no. 1375, as a control. Two bands of degradation are present. Lane 2, the full-length (~100 kDa) protein fused to GST and the larger degradation product bind to RNA.
clones in yeast. Three clones of the same size were selected from a mouse fetal brain cDNA library and the EST clones AA185054, AA219909 and AA139817. The human sequence (3462 bp) was established from the two EST clones AA397665 and AA214642 [with a poly(A) tail].

**Construction of mNUFIP vectors**

The original pASV3 (33) plasmid was digested with SfiI and the insert subcloned in the SfiI site of a modified pBluescript vector. Then this construct was digested with XhoI and SacI and the insert cloned in pTL1 vector, producing pTL-mNUFIP. The insert from pTL-mNUFIP was subcloned into the pEGFP-C2 vector for expression of the GFP-fusion, producing GFP-mNUFIP.

**Construction of hNUFIP vectors**

The two overlapping EST clones AA397665 and AA214642 were digested with EcoRI–PstI and PstI–KpnI, respectively, and cloned in the EcoRI and KpnI sites of the vector pTL1. This plasmid was named pTL-hNUFIP. The plasmid pTL-hNUFIP was digested with EcoRI and cloned in the pEGFP-C2 vector (Clontech, Palo Alto, CA), producing GFP–hNUFIP. Deletion constructs were constructed by amplification of the plasmid pTL-hNUFIP with the forward primers GGGGAATTCATGCCGCTGCTGCCAACTGCTTGCTTG, containing an EcoRI restriction site, and the reverse primers GGGAATTCATGGCCTGGCCTCTGG, both containing an EcoRI restriction site, and the reverse primers GGGAATTCATGCCGCTGCTGCCAACTGCTTGCTTG, containing a BglII restriction site. The PCR fragments were digested with EcoRI and PstI or EcoRI and BglII, respectively, cloned in the vector pBTM116m (27), and digested with the appropriate restriction enzymes. The PCR reaction was as described above.

**Antibody against hNUFIP**

A synthetic polypeptide ENRKKSFEKTNPKRKDKDYHIN corresponding to amino acids 421–442 of the hNUFIP was coupled to ovalbumin (Ovalbumin-MBS; Sigma-Aldrich) and used for immunization of rabbits using standard protocols. The antiserum was purified on an affinity column coupled to the same peptide used for immunization, according to the manufacturer’s instructions (Sulfolink coupling gel; Pierce, Rockford, IL).

**GST pull-down assay**

Full-length and deletion constructs were produced by in vitro transcription-translation in rabbit reticulocyte lysate or wheat germ extract in the presence of [35S]methionine (ICN, Orsay, France), according to the manufacturer’s instructions (Promega, Madison, WI).

In vitro translated proteins were mixed with 1 mg of GST-fused protein (FMRP produced in a baculovirus system or hNUFIP produced in bacteria) or with 1 mg of GST. GST pull-down assays were carried out in the following buffer: 20 mM Tris–HCl pH 7.5, 100/200/500 mM NaCl, 5 mM EGTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), as described (24).

**Immunoprecipitation**

HeLa cells or transfected COS cells were lysed in the following buffer: 500 mM NaCl, 20 mM Tris–HCl pH 7.5, 2% Triton X-100, 1 mM PMSF. The immunoprecipitation was carried out in the lysis buffer as described (37) and indicated in the legends to the figures. The proteins bound to the beads were separated by electrophoresis on 8–12% SDS–polyacrylamide gel and visualized by immunoblot using the IC3 antibody (8), no. 566 antibody (28) or no. 1375 (this study).

**Construction of human FXR1 and FXR2 vectors**

FXR1 and FXR2 (30) were amplified using the forward primers GGGAATTCATGGCGGACGTGACGGTGGAGG and GGGAATTCATGGCGGACGTGACGGTGGAGG, both containing an EcoRI restriction site, and the reverse primers GGCGGATCCATGCAAGTTGTTTTGTGCTCATGCTCACCTTCATTTTACTTTCAGTATAAAATTCTC, GGGAATTCATGCCGCTGCTGCCAACTGCTTGCTTG, containing a BglII restriction site. The PCR fragments were digested with EcoRI and PstI or EcoRI and BglII, respectively, cloned in the vector pBTM116m (27), and digested with the appropriate restriction enzymes. The PCR reaction was as described above.

**Cell transfection and immunofluorescence detection**

Transfection of COS and HeLa cells, cell fixation and immunodetection with the IC3 monoclonal antibody were carried out as previously described (11). Polyclonal antibody no. 1375 was diluted 1:8000. Double-label immunofluorescence experiments were performed by separate sequential incubations of each primary antibody diluted in phosphate-buffered saline (PBS) (incubation at 4°C overnight), followed by the specific secondary coupling to TXRD or OG (Jackson Immunoresearch Laboratories, West Grove, PA) (incubation at room temperature for 1 h). The light microscope was a Leica (Wetzlar, Germany) LEITZ DMRD. Confocal images were obtained with a Leica TCS4D microscope. Images were colourized and merged using the Adobe Photoshop software program.

**In situ hybridization on tissue sections**

In order to obtain sense and antisense RNA probes, mNUFIP and FMR1 cDNAs cloned in pBluescript were linearized by digestion with XhoI or SacI and with EcoRI or SpeI, respectively. In vitro transcription and in situ hybridization were performed as previously described (38).

**Production and purification of NUFIP recombinant protein in bacteria**

The hNUFIP gene was cloned in the EcoRI site of the pGEX-4T1 (Pharmacia, Uppsala, Sweden) expression vector and transformed in the BL21 bacterial strain. After induction with 0.5 mM isopropyl-b-D-thiogalactopyranoside (IPTG) for 24 h at 25°C, purification of the protein was performed according to the manufacturer’s instructions (Pharmacia).
REFERENCES


